| CDP-1 (cetuximab biosimilar) / Guilin SanJin Group |
NCT03491709: A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC |
|
|
| Unknown status | 1 | 18 | RoW | anti-EGFR monoclonal antibody, CDP1, Cetuximab injection, Erbitux | Dragonboat Biopharmaceutical Company Limited, Shanghai East Hospital | Colorectal Cancer | 09/19 | 12/19 | | |
NCT03881787: Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux |
|
|
| Unknown status | 1 | 84 | RoW | anti-EGFR monoclonal antibody, CDP1, Cetuximab injection, Erbitux | Dragonboat Biopharmaceutical Company Limited, West China Hospital, Shanghai Public Health Clinical Center | Healthy Volunteers | 10/19 | 12/19 | | |
NCT04151810: Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors |
|
|
| Unknown status | 1 | 30 | RoW | CDP1, Recombinant anti-EGFR human mouse chimeric monoclonal antibody | Dragonboat Biopharmaceutical Company Limited | Advanced Tumors | 12/20 | 06/21 | | |
NCT04739111: An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor |
|
|
| Recruiting | 1 | 130 | RoW | Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1), LDP combined with CDP1 | Dragonboat Biopharmaceutical Company Limited, West China Hospital | Advanced Malignant Tumor | 02/23 | 02/24 | | |
ChiCTR2100052484: To evaluate the exploratory clinical study of all human anti-PD-L1 antibody injection (LDP) combined with recombinant anti EGFR human mouse chimeric monoclonal antibody injection (cdp1) in patients with advanced malignant tumors |
|
|
| Recruiting | 1 | 130 | | CDP1 combined with LDP | West China Hospital of Sichuan University; Dragonboat Biopharmaceutical, Co., Ltd., self-funded | Advanced malignant tumor | | | | |
